Journal
NATURE BIOTECHNOLOGY
Volume 39, Issue 2, Pages 135-143Publisher
NATURE RESEARCH
DOI: 10.1038/s41587-021-00814-w
Keywords
-
Categories
Ask authors/readers for more resources
Facing the absence of face-to-face meetings, FDA and industry have implemented regulatory workarounds to maintain drug and biologics approvals, and this trend may continue in the long term.
In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
